Artiva Biotherapeutics CMO Subhashis Banerjee disposes of 429 common shares worth $5,148 under 10b5-1 plan
Reuters2026/08/20 01:01- Artiva Biotherapeutics Chief Medical Officer Subhashis Banerjee sold 429 common shares on Aug. 18 at USD 12.
- The sale followed an option exercise for 429 shares at USD 1.92.
- Directly held common stock ended at 144,963 shares.
- Employee stock options outstanding ended at 79,571.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Australian Dollar reacts little to dismal jobs data; holds above weekly low vs weaker JPY
Axtel reappoints Deloitte as external auditor
Camera-equipped AirPods Pro 3 rumor turns out to be a false leak! Supply chain challenges remain unresolved, Apple (AAPL.US) still targets a 2027 release for its new AI earphones
Despite reports that Apple may accelerate its plan to launch AirPods equipped with cameras, the plan is still scheduled to be implemented in 2027 as originally planned.
Storage capacity negotiations scheduled until 2030! Winbond Electronics initiates expansion plans ahead of schedule
Winbond Electronics has initiated an early expansion plan for Module B at its Lujhu plant in Kaohsiung, with construction expected to begin in 2027 and equipment installation in 2029. Customer capacity negotiations have already been scheduled through 2029 to 2030. The institution believes that AI-driven demand for storage will “continue for quite a long time.” In addition, Winbond has invested approximately 4 billion yuan in the silicon capacitor production line, with mass production expected as early as 2027. This is regarded as a third growth driver beyond logic and storage.
Crypto prices
More
